Literature DB >> 6589212

Analysis of a human osteogenic sarcoma antigen and its expression on various human tumour cell lines.

D G Campbell, M R Price, R W Baldwin.   

Abstract

The murine monoclonal antibody 791T/36 cross-reacts with cells other than the immunizing osteogenic sarcoma cell line 791T, upon which the 791T/36-defined epitope is expressed on a protein of apparent molecular weight 72,000. An investigation was performed to determine whether the epitope occurred on similar molecules on other cell lines. Radiolabelled immunoprecipitates, prepared with the 791T/36 antibody, from three osteogenic sarcoma cell lines (2 OS, 788T and 278T), the prostate carcinoma EB33 and the colon carcinoma HcLo each contained a protein with a molecular weight of 72,000 as the major constituent, together with, in some cases, material of lower molecular weight. This heterogeneity was shown by neuraminidase treatment of the immune precipitates to be due to variations in sialic acid content of the antigens since, in five of the six cell lines tested, such treatment produced homogeneous material of apparent molecular weight 55,000. Chymotrypsin treatment of the immune precipitates produced in each instance a major polypeptide of molecular weight 47,000 which displayed no microheterogeneity. Immunoadsorbent-purified antigen from 791T cells was shown to bind strongly to Sepharose-wheat-germ agglutinin and less to Sepharose-concanavalin A, confirming the glycoprotein nature of this antigen. These studies demonstrate that molecules expressing the 791T/36-defined epitopes on different tumour cell lines are glycoproteins which display heterogeneity with respect to apparent molecular weight that is attributable to varying degrees of sialylation. No apparent differences were detected in the polypeptide "backbone" of these antigenic molecules.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6589212     DOI: 10.1002/ijc.2910340107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Authors:  L G Durrant; V S Byers; P J Scannon; R Rodvien; K Grant; R A Robins; R A Marksman; R W Baldwin
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

2.  The localization of anti-tumour monoclonal antibodies in colorectal cancer.

Authors:  N C Armitage
Journal:  Ann R Coll Surg Engl       Date:  1986-11       Impact factor: 1.891

3.  Patterns of reactivity of the monoclonal antibody 791T/36 with different tumour metastases in the liver.

Authors:  C J Hawkey; C H Holmes; P G Smith; E B Austin; R W Baldwin
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.